Particle-based platforms for malaria vaccines

Authors

Yimin Wu, Laboratory Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Rockville, MDFollow
David L. Narum, Laboratory Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, Rockville, MD
Sylvain Fleury, Mymetics Corp., 4 Route de la Corniche, 1066 Epalinges, Switzerland
Gary Jennings, Cytos Biotechnology AG, Wagistrasse 25, 8952 Schlieren, Switzerland
Anjali Yadava, Malaria Vaccine Branch, U.S. Military Malaria Vaccine Program, Walter Reed Army Institute of Research, Silver Spring, MD

Document Type

Article

Date of this Version

2015

Citation

Vaccine 33 (2015) 7518–7524

Comments

U.S. Government Work

Abstract

Recombinant subunit vaccines in general are poor immunogens likely due to the small size of pep-tides and proteins, combined with the lack or reduced presentation of repetitive motifs and missing complementary signal(s) for optimal triggering of the immune response. Therefore, recombinant sub-unit vaccines require enhancement by vaccine delivery vehicles in order to attain adequate protective immunity. Particle-based delivery platforms, including particulate antigens and particulate adjuvants,are promising delivery vehicles for modifying the way in which immunogens are presented to both theinnate and adaptive immune systems. These particle delivery platforms can also co-deliver non-specific immunostimodulators as additional adjuvants. This paper reviews efforts and advances of the Particle-based delivery platforms in development of vaccines against malaria, a disease that claims over 600,000lives per year, most of them are children under 5 years of age in sub-Sahara Africa.